Total amount: € 0,00
Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index
HEPATOLOGY IN 2009
Pan J.-J., Firpi R. J.
Section of Hepatobiliary Diseases and Liver Transplantation Division of Gastroenterology, Hepatology and Nutrition Department of Medicine, University of Florida, Gainesville, FL, USA
Hepatitis C is a serious public health problem with more than 170 million chronic carriers worldwide. Although hepatitis C infection can be cured in up to 40% of patients, current treatment is not ideal and is associated with a wide spectrum of side effects and complications. Therefore, emerging evidence suggests that patients can receive tailored therapy based on their viral kinetic changes during treatment. With better knowledge of hepatitis C viral genome and life cycle, compounds so called “Specifically Targeted Antiviral Therapy for HCV or STAT-C” are under development. This review will discuss current therapies and recent advances in new therapies for hepatitis C.